|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette.
|
31754210 |
2020 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma characterized by large anaplastic cells with diffuse and uniform CD30 reactivity.
|
31495882 |
2020 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphomas (ALCLs) encompass a group of CD30(+) non-Hodgkin T-cell lymphomas.
|
31706671 |
2020 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty-nine cases (41 patients) with CD8+ CTCLs/LPDs were examined, including CD8+ mycosis fungoides (MF) (n = 14), aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (AETCL) (n = 8), subcutaneous panniculitis-like T-cell lymphoma (SPTCL) (n = 7), CD30+ LPDs (n = 6), primary cutaneous γδ T-cell lymphoma (GDTCL) (n = 6), and others (n = 8).
|
31355940 |
2020 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a CD30-positive T cell lymphoma, a rare type of non-Hodgkin lymphoma.
|
31667195 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30+ cutaneous extranodal natural killer/T-cell lymphoma presented peculiar clinicopathological features and had more favorable disease course in patients with cutaneous dissemination from nasal disease.
|
30597548 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Though rare, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a CD30+ T-cell lymphoma associated with textured breast implants, has adversely impacted our perception of the safety of breast implants.
|
31316085 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery.
|
30715169 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Of note, brentuximab vedotin is an antibody-drug conjugate that targets CD30, another lymphocyte antigen expressed on the cell surface of both Hodgkin lymphoma (a variant of B-cell lymphoma) and some T-cell lymphomas.
|
31580408 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD8<sup>+</sup> lymphomatoid papulosis is frequently indistinguishable histopathologically from primary cutaneous aggressive epidermotropic CD8<sup>+</sup> T-cell lymphoma except for the expression of CD30.
|
30520526 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies.
|
30526166 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD3+, CD56+, CD4-, CD8-, CD20-, CD30- Peripheral T-Cell Non-Hodgkin's Lymphoma: A Rare Case Report.
|
28400642 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the few cases reported herein, one might suggest that the prognosis mirrors that seen in other forms of cutaneous T cell lymphoma with mature small cell dominant infiltrates exhibiting an indolent pattern while a CD30 negative large cell T cell lymphoma would be expected to demonstrate an aggressive clinical course.
|
30572149 |
2019 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR T cells with novel target antigens, including CD20, CD22, and κ-light chain for B-cell lymphomas, and CD30 for Hodgkin and T-cell lymphomas, are currently being investigated in clinical trials.
|
28857075 |
2018 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
T-cell lymphoma represented 78.7% of all cases, the majority being early mycosis fungoides (MF) (64%; median age: 66 years), followed by lymphomatoid papulosis (LyP) (19%; median: age 48 years), and others (median age: 72 years), including eight cases of anaplastic large CD30+ T-cell lymphoma, four CD4+ small-medium pleomorphic T-cell lymphoproliferative disorder, four Sézary syndrome, one subcutaneous panniculitis-like T-cell lymphoma, one extranodal NK/T-cell lymphoma nasal-type, and one angioimmunoblastic T-cell lymphoma.
|
29171395 |
2018 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More than 500 women worldwide have developed a CD30+ T-cell lymphoma around breast implants, strongly suggesting a cause-and-effect relationship, and designated as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL).
|
29689246 |
2018 |
|
T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the antibody drug conjugate, brentuximab vedotin has been shown to have potent activity in T cell lymphomas expressing CD30.
|
29397528 |
2018 |
|
T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we report that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 that mediates histone H3 lysine 27 trimethylation, is overexpressed in CD30+ anaplastic cells in primary cutaneous anaplastic T-cell lymphoma and large-cell transformed cutaneous T-cell lymphoma.
|
29248547 |
2018 |
|
T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma.
|
28454236 |
2017 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell non-Hodgkin lymphoma with 2 main clinical presentations: primary cutaneous ALCL (pcALCL) and systemic ALCL (sALCL).
|
28626950 |
2017 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we present four different cases of CD30-positive T-cell lymphoma with cutaneous manifestations.
|
28225962 |
2017 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease.
|
28965629 |
2017 |
|
T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transformation of Sézary syndrome into CD30+ anaplastic large T-cell lymphoma after alemtuzumab therapy with evidence of clonal unity.
|
25548993 |
2015 |
|
T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The patient was tentatively diagnosed with primary cutaneous CD30-negative large T-cell lymphoma with aberrant CD20 co-expression, pending workup to exclude systemic lymphoma with cutaneous involvement.
|
25942672 |
2015 |
|
T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We report a case of 39-years-old male of primary splenic NK/T cell lymphoma with bone marrow involvement and CD30 positive expression.
|
25183396 |
2014 |